Kornimate/medical-research-clean huggingface dataset:
evaluation of the effect of myopic femtosecond laser assisted-lasik on anterior chamber flare values and corneal endothelial cells: a prospective before-and-after study

Conditions: Cornea; Refractive Surgery; Anterior Chamber Inflammation

Summary: this study aimed to investigate whether femtosecond laser-assisted lasik (fs-lasik) surgery causes inflammation in the anterior chamber and to analyze its effect on endothelial cells.

since fs-lasik surgery is applied using both an fs laser and an excimer laser, we aimed to determine the direct and indirect effects of these applications on the corneal endothelium, the intensity of the inflammation, and the blood-aqueous barrier in the anterior chamber. to the best of our knowledge, the effects of fs-lasik on anterior chamber inflammation have not been previously investigated. therefore, we evaluated these effects using objective measurement methods, such as specular microscopy and laser flare photometry.

Eligibility criteria:
inclusion criteria: * the patients who performed femtosecond laser assisted lasik for myopia or myopic astigmatism. * uncomplicated surgery exclusion criteria: * complicated surgery, * hyperopic or hyperopic astigmatism * lack of follow-up measurements

Keywords: excimer laser corneal endothelium laser in situ keratomileusis (lasik); femtosecond assisted-lasik anterior chamber flare endothelial cell densit corneal endothelium
buprenorphine transdermal patch in subjects with osteoarthritis pain requiring opioids. includes a 52-week safety extension.

Conditions: Osteoarthritis

Summary: the original objective of this study was to assess the safety and efficacy of the buprenorphine transdermal system (btds) (5, 10, and 20) in comparison to placebo transdermal system in subjects with moderate to severe osteoarthritis pain. however, this study was terminated early with only 35% of the planned sample size, therefore the primary objective is changed to focus on the safety evaluations.

buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Eligibility criteria:
inclusion criteria: * clinical evidence of osteoarthritis of the hip, knee, or spine joint for ≥ 1 year currently adequately treated with short acting opioids. * taking ≥ 30 and ≤ 80 mg oral morphine or morphine equivalents per day for ≥ 2 weeks for control of their osteoarthritis pain. exclusion criteria: * requiring frequent analgesic therapy for chronic condition(s), other than osteoarthritis of the hip, knee, or spine. * scheduled for surgery of the disease site (e.g., major joint replacement surgery), or any other major surgery that would fall within the study period. other protocol-specific exclusion/inclusion criteria may apply.

Keywords: osteoarthritis opioid transdermal
comparison of pre-oxygenation of niv and hfnc therapy for intubation of icu patients with acute respiratory failure

Conditions: Acute Respiratory Failure; Intratracheal Intubation

Summary: the aim of the study is to evaluate the incidence of severe hypoxemia episodes during the intubation procedure with two methods of pre-oxygenation: 1. niv (non invasive ventilation) 2. hfnc (high-flow nasal canula oxygen therapy)

design: clinical randomized, open, multicenter, comparative trial, with parallel groups aimed at evaluating a medical device. selection of patients admitted to the icu for acute respiratory failure, requiring endotracheal intubation. randomized study, inclusion in two groups: niv or hfnc. experimental group: nhfc group, preoxygenation by nhfc: oxygen flow rate of 60 l / min and 100% fio2. control group: niv group, preoxygenation by niv: pressure support set for an exhaled tidal volume of 6-8 ml / kg of ideal body weight, peep of 5 cm h2o and fio2 at 100%. duration of participation of each patient: 28 days

Eligibility criteria:
main inclusion criteria: * acute hypoxemic respiratory failure requiring endotracheal intubation main exclusion criteria: * coma * niv contraindication
pyrexia management using an il-6 antibody in braf+ melanoma patients treated with dabrafenib/ trametinib +/- immunotherapy

Conditions: Pyrexia

Summary: the study examines the development of fever after administration of actemra (tocilizumab) in patients who have fever and other cytokine release symptoms (headache, nausea, palpitations, low blood pressure) due to cancer therapy (tafinlar (dabrafenib) / mekinist (trametinib) +/- immunotherapy) . the goal of the study is to better understand the side effects and to find an effective therapy against them.


Eligibility criteria:
inclusion criteria: 1. informed consent as documented by signature 2. subjects (males and females) age ≥ 18 years 3. ecog \< 3 4. subjects with pyrexia grade 1\*- 4 and elevated crp with persistent fever after one day of antipyretic therapy with or without at least one other additional symptom of cytokine release syndrome such as nausea, headache, tachycardia, hypotension, maculopapular rash, shortness of breath, transaminitis, renal failure, dehydration 5. elevated crp serum levels further than normal baseline levels (\> 3.0 mg/l) 6. subjects with resected, non-resectable, adjuvant or metastatic braf+ melanoma treated with : * braf inhibitor (dabrafenib) in combination with mek inhibitor (trametinib) * braf inhibitor (dabrafenib) in combination with mek inhibitor (trametinib) preceded by therapy with anti-pd-1/pd-l1 and/or anti ctla-4 inhibitor * braf inhibitor (dabrafenib) in combination with mek inhibitor (trametinib) plus anti-pd- 1/pd-l1 inhibitor
impact of fas/fasl in chemotherapy response in epithelial ovarian carcinoma

Conditions: Ovarian Carcinoma

Summary: ovarian carcinoma has poor prognosis and new therapeutic strategies are required. many patients with ovarian carcinoma showed resistance to chemotherapy. cleaved fasl is known for induced atypical response when is binding to fas such as avoiding apoptosis and inducing cell motility.


Eligibility criteria:
pre-inclusion criteria: - patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (ct) inclusion criteria: * pathological ovarian carcinoma diagnosed at pathological analysis after surgery. * neo adjuvant chemotherapy exclusion criteria: * no neo-adjuvant chemotherapy * no ovarian carcinoma at final pathological analysis * less than 18 years old.
changes in ios in ipf

Conditions: Idiopathic Pulmonary Fibrosis

Summary: idiopathic pulmonary fibrosis (ipf) is a condition where scar tissue (called fibrosis) builds up in the lungs. it usually gets worse over time. fibrosis causes the lungs to become stiff, and reduces the amount of oxygen that the lungs can take up. people with ipf complain of worsening breathlessness, which limits their day to day activities. lung function tests are breathing tests that measure how well your lungs are working, and are used by doctors to decide whether to start or stop medicines in people with ipf. however, people with ipf tell us that lung function tests require a lot of effort, can make them cough and feel very short of breath. about 1 in 5 people with ipf are unable to perform lung function results accurately. this might unfairly lead to some people with ipf not receiving the right medications or for their medications to be stopped too soon. impulse oscillometry (ios) uses sound waves to measure the stiffness of the lung, and has been used successfully in children who are unable to perform normal lung function tests. the overall aim of the research is to see whether changes in ios measures can give useful information about the lungs in patients with ipf; for example, by judging the overall impact of the disease on the lungs, or predicting future deterioration. we will look at how ios changes over time in patients with ipf, and to see whether these measurements can tell us about whether ipf is getting worse or predict important health events, such as hospital admission. we will compare change in ios with changes in other tests used to monitor ipf and with patient reported ratings of change in their condition. this will help decide the amount of ios change that is noticed and considered meaningful by people with ipf.


Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic pulmonary fibrosis made by specialist multidisciplinary team according to international standards 2. able to provide written informed consent exclusion criteria: 1. contraindication to performing conventional lung function tests, e.g untreated tb, haemoptysis, pneumothorax, unstable cardiovascular status, recent eye, thoracic or abdominal surgery, thoracic, abdominal or cerebral aneurysm, acute illness (including diarrhoea and vomiting). 2. unable to create seal on mouthpiece
effects of propofol-dexmedetomidine on immune function in patients with cancer larynx

Conditions: Cancer Larynx; Total Laryngectomy

Summary: the aim of this prospective, randomized clinical study is to compare between propofol and isoflurane on perioperative immune cell populations and function in patients undergoing total laryngectomy surgery.

the perioperative period might be a critical time in primary cancer surgery because many factors can affect whether recurrence, or metastasis , or elimination by the immune system. cancer surgery can induce an acute inflammatory response, due to local tissue damage and the shedding of malignant cells into the blood and lymphocytic circulation although meticulous surgical manipulation. many evidences suggest that several factors during the perioperative period can affect the immune system. these could be attributed to the surgery per se, pain, anxiety, hypothermia, blood transfusion, anesthetic technique, and anesthetic drugs .impairment in the immune system may allow malignant cells to escape immuno-surveillance and metastasize in the perioperative period.as well as increase the risk of postoperative complications, such as systemic inflammatory response syndrome, sepsis, and multi-organ failure. previous retrospective clinical studies of both breast and prostate cancer surgery have suggested an association between anaesthetic technique and cancer recurrence. however ,other retrospective trials on various forms of cancer have shown no such benefit.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status i- iii * scheduled for total laryngectomy. exclusion criteria: * patients refusal. * morbid obese patients (body mass index \>40 kg/m2). * allergy to local anesthetics agents used. * severely altered consciousness level. * psychiatric disorders. * severe or uncompensated cardiovascular disease. * severe renal disease. * severe hepatic disease. * severe endocrinal diseases.
china diabetes cardiovascular initiative

Conditions: Acute Coronary Syndrome; Diabetes Mellitus

Summary: as a collaborative project between american heart association, chinese society of cardiology, american diabetes association and chinese diabetes society, the china diabetes cardiovascular initiative aims to enhance the attention and awareness of cardiovascular health care professionals (hcps) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.


Eligibility criteria:
inclusion criteria: 1. patients hospitalized with acute coronary syndrome and diabetes. 2. aged at least 18 years. exclusion criteria: none
antifungal prophylaxis with micafungin after cord blood allogeneic stem cell transplantation (mycacoord)

Conditions: Invasive Fungal Infection

Summary: infections due to post transplant immune deficiency are a major problem following allogeneic stem cell transplantation (allo-sct), particularly in patients receiving cord blood transplant (cb). duration of neutropenia is one of the most important risk factor for invasive fungal infection (ifi). in this setting, micafungin has been approved for antifungal prophylaxis for patients undergoing allo-sct. in a randomized, double-blind, comparative, phase iii trial, the overall efficacy of micafungin was superior to that of fluconazole as antifungal prophylaxis during the neutropenic phase after allo-sct. however, very few patients in this study received a cb transplant. this is phase iib, prospective, open-label, non-comparative study to assess the safety of micafungin when use in prevention of ifi in neutropenic patients receiving allo-sct using cb as source of stem cells.


Eligibility criteria:
inclusion criteria: * adult patients receiving allo-stem cell transplantation using cord blood as source of stem cells (cf conditioning regimen recommendation). * sex male or female * age between 18 and 65 years at the time of signing the informed consent form. * diagnosis of an hematologic disease for who a allograft decision has been taken * not having a (hla)-matched related or unrelated donor within two month after complete remission achievement * able to understand and voluntarily sign an informed consent form. * subjects affiliated with an appropriate social security system * male, female without childbearing potential or negative urine pregnancy test at the screening visit prior to beginning the treatment. women of childbearing potential must be following adequate contraceptive measures. men must agree to use an acceptable method of contraception (for themselves or female partners) for the duration of the study * each subject will weigh 40 kg or more exclusion criteria: * any suspected or documented invasive fungal infection at study entry or at any time prior to study entry * use of any systemic antifungal therapy within 72 hours prior to study entry * known history of allergy, hypersensitivity or intolerance to echinocandin agents * patient with any medical, psychological or social condition, which in the opinion of the investigator could increase the risk to the patient, or decrease the chance of obtaining satisfactory data to achieve the objectives of this study. * participation in a study testing a new drug or a new conditioning * hiv, hbv or hcv positive * pregnant or breast feeding females. * subject protected by law.

Keywords: adult allo-stem cell transplantation cord blood
evaluating the impact of evidence-based information about mammography on breast cancer screening decisions

Conditions: Breast Cancer

Summary: patient decision aids are tools that help guide individuals through a healthcare-related decision making process. they help users combine evidence-based information and recommendations by a health care provider with their personal needs, values and preferences. through this project, dr. dobbins and her research team will explore whether the use of patient decision aids with high-quality and user-friendly summaries of research evidence, or summaries of research evidence alone, help to improve the quality of decision making by women facing breast cancer screening decisions.

guidelines for breast screening in canada are based on low-moderate quality evidence of effectiveness and screening is associated with potential harms. patient decision aids (pdas) are tools that assist users to understand treatment options, risks and benefits to align decisions with values and preferences. the investigators would now like to know whether use of a pda alongside evidence-based information provided through the mcmaster optimal aging portal, or simply access to evidence-based information alone, can help users to make informed decisions about breast cancer screening in women.

Eligibility criteria:
inclusion criteria: * english speaking women, 40-49 years old * residents of british columbia, nova scotia, and prince edward island exclusion criteria: * history of breast cancer or mammography in the last 12 months * classified as above-average risk for breast cancer (i.e., known genetic mutation linked to bc; no genetic testing, but a parent, sibling or child with a genetic mutation linked to bc; or received chest wall radiation before age 30)

Keywords: screening mammography patient decision aid
qst-pupillometry in sickle cell disease patients

Conditions: SCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab)

Summary: there has been little progress for effective treatment of pain in sickle cell disease (scd) patients. many organizations have recognized that understanding the causes and reducing the burden of pain in scd is critical in order to improve the quality of life in scd patients. as patients with scd face the challenge of living with both acute and chronic pain which is often improperly treated, our translational and interdisciplinary project aims to identify objective measures of pain sensitivity and its biochemical and genetic correlates. we hypothesize that scd patients will have decreased tolerance to thermal and electrical stimuli.


Eligibility criteria:
inclusion criteria: * scd with severe phenotype (hbss, hbsbeta0 thalassemia, hbsoarab) * relatives of scd patients who do not have sickle cell trait or scd; healthy controls exclusion criteria: * completed overt clinical stroke or transient ischemic attack; * known severe vasculopathy or moyamoya disease on brain mra (magnetic resonance angiography). * history of having consumed alcohol within the last 12 hours prior to testing.
stress ball used in the active phase of labor on labor pain and birth comfort

Conditions: Labor Pain; Birth Order; Stress

Summary: the aim of the clinical trial is to examine the effect of a stress ball applied to pregnant women during the active phase of labor on labor pain and labor comfort. the effect of the stress ball used in the experimental group on labor pain and labor comfort will be evaluated. the stress ball applied to pregnant women during the active phase of labor minimizes labor pain and increases labor comfort h 0: the stress ball used during the active phase of labor has no effect on labor pain and labor comfort. h 1: the stress ball used during the active phase of labor increases labor pain and labor comfort. the researchers will monitor the pregnant women from the time the cervical dilation is 3-4 cm (from the active phase of labor) until the cervical dilation is 8-9 cm and the experimental group will be asked to use the stress ball. routine application will be made to the control group. the pain during labor of the experimental and control groups will be evaluated with the vas scale. after the birth, the labor comfort scale will be applied to measure labor comfort.


Eligibility criteria:
inclusion criteria: * vaginal birth * pregnant women between the ages of 18-40 exclusion criteria: * risky pregnancy

Keywords: active phase of labor, stress ball, labor pain, labor comfort
gonadotropin-releasing hormone (gnrh)-antagonist therapy in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to compare the safety and efficacy of gonadotropin-releasing hormone (gnrh) antagonist therapy versus placebo in patients with moderate to severe rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * adult between 18 years and above * moderate to severe disease activity * negative pregnancy test for women of childbearing potential * use of reliable method of contraception (non-hormonal) by sexually active female patients exclusion criteria: * patients who are pregnant or breastfeeding * patients taking biologic therapy or prednisolone \>7.5mg
a study of juvenile idiopathic arthritis patients given abatacept and the number of infections or malignancies that occur

Conditions: Juvenile Idiopathic Arthritis

Summary: this study will determine the incidences of infections and malignancies among jia patients treated with abatacept


Eligibility criteria:
inclusion criteria: * two diagnoses of jia (icd-9 code 714.3x) within 90 days * age less than 18 years at the time of second of the two diagnoses * index date is the date of initiating treatment with abatacept exclusion criteria: * greater than or equal to 18 years of age
impact of covid-19 pandemic on early spontaneous abortions and early termination of pregnancy

Conditions: Termination of Pregnancy; Covid19; Pregnancy Loss

Summary: to see the impact the covid-19 pandemic has had on early spontaneous abortions and early termination of pregnancy in the first trimester

to date, the research has focused on the complications of sars-cov-2 in pregnant women. there is no research in the literature that has compared the rates and behavior of miscarriage during the time of the covid-19 pandemic to before the time of the pandemic. as described in the literature, there is an established connection between covid-19 and stress, anxiety, and depression. there is also an established connection between stress, anxiety, and depression and rates of miscarriage. the investigators hereby wish to analyze the effect of the covid-19 pandemic on miscarriages. in this study, the investigators will analyze the number of early missed abortions and number of termination of pregnancies in the first trimester before and during the covid-19 pandemic. the investigators will also analyze the time interval between diagnosis of missed abortion and attendance to e.r in missed abortions during the covid-19 pandemic. in addition, the investigators will be comparing the reasons for termination of pregnancy during this time, as well as analyzing age, religion, and demographic variables during the covid-19 pandemic compared to years prior.

Eligibility criteria:
inclusion criteria: * all women attending for early missed abortion or termination of pregnancy receiving treatment between march 11th - november 30th during the years 2017-2020 gestational age until 12 weeks 6 days (1st trimester only) exclusion criteria: * incomplete and complete abortions * gestational age \>13 weeks